GeneDx Holdings Faces Securities Fraud Class Action Lawsuit
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 day ago
0mins
Source: Globenewswire
- Lawsuit Deadline: GeneDx Holdings Corp. (NASDAQ: WGS) faces a deadline of August 3, 2026, for a securities fraud class action lawsuit, requiring investors to submit necessary documents promptly to participate, or risk losing their claims.
- Investor Losses: The lawsuit alleges that the company and its executives made materially false and misleading statements between April 16, 2025, and May 4, 2026, resulting in artificially inflated stock prices and significant losses for investors when the truth was revealed.
- Class Action Background: The lawsuit represents a class of investors claiming violations of the Securities Exchange Act of 1934, which impacted the company's business operations, growth prospects, and financial stability, potentially undermining investor confidence.
- Law Firm Credentials: Bernstein Liebhard LLP has recovered over $3.5 billion for clients since 1993 and has been recognized multiple times on The National Law Journal’s “Plaintiffs’ Hot List,” showcasing its strong capabilities in protecting investor rights.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy WGS?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on WGS
Wall Street analysts forecast WGS stock price to rise
8 Analyst Rating
7 Buy
1 Hold
0 Sell
Strong Buy
Current: 56.420
Low
155.00
Averages
171.43
High
200.00
Current: 56.420
Low
155.00
Averages
171.43
High
200.00
About WGS
GeneDx Holdings Corp. is a genomics company. The Company operates, through its subsidiary, GeneDx, LLC, which is focused on exome and genome tests that translate complex genomic data into clinical answers that unlock personalized health plans, accelerate drug discovery, and improve health system efficiencies. It operates through the GeneDx segment, which primarily provides pediatric and rare disease diagnostics with a focus on whole exome and genome sequencing and, to a lesser extent, data and information services. Genomic sequencing tests include whole genome sequencing, whole exome sequencing, prenatal genetic testing, targeted testing, pediatric neurology, general pediatrics, geneticists and genetic counsellors, and others. It offers a menu of targeted variant testing options to meet the needs of families and healthcare providers. Its subsidiary, Fabric Genomics, Inc., specializes in artificial intelligence-powered genomic interpretation.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
GeneDx Holdings Faces Securities Fraud Class Action Lawsuit
- Lawsuit Background: GeneDx Holdings Corp. (NASDAQ: WGS) is facing a securities fraud class action lawsuit for alleged material misstatements regarding its acquisition of Fabric Genomics during the period from April 16, 2025, to May 4, 2026, which has significantly impacted investor confidence.
- Acquisition Details: The company announced an agreement to acquire Fabric Genomics for up to $51 million, with $33 million in cash upfront, aiming to expand its market through AI-driven genomic interpretation; however, it later faced significant viability issues with Fabric, leading to investor losses.
- Financial Impact: On May 4, 2026, GeneDx reported a drop in adjusted gross margin and lowered earnings projections, disclosing a $31.3 million impairment loss related to Fabric, causing its stock price to plummet by over 49% following the announcement.
- Investor Action: Affected investors are encouraged to file for lead plaintiff status by August 3, 2026, with KTMC offering free case evaluations and operating on a contingency fee basis, urging investors to take proactive steps to protect their legal rights.
See More
GeneDx Faces Securities Class Action After Stock Plunge
- Stock Price Crash: GeneDx's stock plummeted by $33.42 (-49%) on May 5, 2026, following a disastrous Q1 earnings report, severely undermining investor confidence and exposing the company to a securities class action.
- Deteriorating Financial Performance: The company reported a tenfold increase in net loss compared to the previous year, with the Fabric Genomics unit missing its revenue target by $2.5 million, leading to a $31.2 million impairment charge that significantly impacted overall financial health.
- Revenue Guidance Cut: GeneDx slashed its 2026 revenue guidance by 12%, stating that revenue growth for genome and exome would be at least 20%, a stark decline from earlier projections, indicating a major shift in product mix and negative implications for future growth.
- Legal Investigation Launched: Hagens Berman is investigating whether GeneDx intentionally or recklessly misled investors regarding the true value of Fabric Genomics and its impact on growth expectations, potentially resulting in substantial losses for investors.
See More
GeneDx Shareholder Lawsuit Reminder and Financial Loss Disclosure
- Lawsuit Application Deadline: ClaimsFiler reminds GeneDx shareholders that those who purchased or acquired shares between April 16, 2025, and May 4, 2026, must file lead plaintiff applications by August 3, 2026, to protect their rights in the securities class action lawsuit.
- Declining Financial Performance: GeneDx's financial results released on May 4, 2026, revealed a drop in adjusted gross margin from 74% to 69%, missing revenue estimates for both its exome and genome products, and lowering full-year revenue guidance to $475 million to $490 million from the previous $540 million to $550 million.
- Impairment Loss Disclosure: The company reported a $31.2 million impairment loss related to its acquisition of Fabric Genomics, which was initially expected to broaden its market opportunities, but failed to deliver the anticipated recurring revenue streams.
- Stock Price Plummet Impact: Following the disappointing financial results, GeneDx's stock price fell by $33.42, or 49.2%, significantly undermining investor confidence and potentially prompting more shareholders to join the lawsuit seeking compensation.
See More
GeneDx Securities Class Action: Lead Plaintiff Selection Deadline Approaches
- Severe Investor Losses: GeneDx Holdings Corp. shares plummeted by $33.42, a 49.20% drop, after the company disclosed a $31.2 million impairment loss, significantly undermining investor confidence and impacting the company's market performance.
- Lead Plaintiff Application Deadline: Investors must file their motions by August 3, 2026, to seek lead plaintiff status; those who miss this deadline can still participate as absent class members in any future settlement or judgment, ensuring their rights are preserved.
- Importance of Lead Plaintiff: Under the Private Securities Litigation Reform Act of 1995, the lead plaintiff directs the litigation on behalf of the entire class, making it crucial to select an investor with substantial losses to effectively represent the collective interests of shareholders.
- Litigation Process Overview: After the deadline, the court will consolidate competing lead plaintiff motions and evaluate which applicants meet PSLRA requirements, a process that typically takes several weeks, ensuring that the appointed lead plaintiff can effectively manage the case proceedings.
See More
Class Action Lawsuit Announced for GeneDx Holdings Corp.
- Class Action Initiation: Rosen Law Firm has announced a class action lawsuit on behalf of purchasers of GeneDx Holdings Corp. (NASDAQ:WGS) common stock between April 16, 2025, and May 4, 2026, indicating potential losses for investors due to misrepresentations.
- Compensation Structure: Investors joining the lawsuit can do so without any out-of-pocket expenses, as the law firm operates on a contingency fee basis, thereby reducing financial barriers and encouraging more affected parties to participate.
- Lawsuit Context: The lawsuit alleges that GeneDx made false statements regarding the impact of its acquisition of Fabric, misleading investors into believing that the acquisition would enhance financial performance, which resulted in losses when the truth emerged.
- Law Firm Reputation: Rosen Law Firm is recognized for its successful track record in securities class actions, having recovered over $438 million for investors in 2019 alone, showcasing its expertise and influence in handling similar cases.
See More
GeneDx Faces Class Action Lawsuit Risks
- Class Action Initiation: GeneDx Holdings Corp. is facing a class action lawsuit due to false statements made between April 16, 2025, and May 4, 2026, with investors able to apply as lead plaintiffs by August 3, 2026, indicating significant legal risks for the company.
- Financial Loss Disclosure: The Q1 2026 financial report revealed a drop in adjusted gross margin from 74% to 69%, and projected earnings were revised down from $540-$555 million to $475-$490 million, directly impacting the company's financial health.
- Acquisition Impact Revealed: Following the acquisition of Fabric Genomics, GeneDx reported a $31.3 million impairment loss, highlighting significant issues with the acquisition decision that could threaten future operations.
- Stock Price Plunge Reaction: Following the earnings report, GeneDx's stock price plummeted over 49%, reflecting strong market concerns regarding the company's financial condition and management transparency, which may lead to decreased investor confidence.
See More
GeneDx Holdings Faces Securities Fraud Class Action Lawsuit
- Lawsuit Background: GeneDx Holdings Corp. (NASDAQ: WGS) is facing a securities fraud class action lawsuit for alleged material misstatements regarding its acquisition of Fabric Genomics during the period from April 16, 2025, to May 4, 2026, which has significantly impacted investor confidence.
- Acquisition Details: The company announced an agreement to acquire Fabric Genomics for up to $51 million, with $33 million in cash upfront, aiming to expand its market through AI-driven genomic interpretation; however, it later faced significant viability issues with Fabric, leading to investor losses.
- Financial Impact: On May 4, 2026, GeneDx reported a drop in adjusted gross margin and lowered earnings projections, disclosing a $31.3 million impairment loss related to Fabric, causing its stock price to plummet by over 49% following the announcement.
- Investor Action: Affected investors are encouraged to file for lead plaintiff status by August 3, 2026, with KTMC offering free case evaluations and operating on a contingency fee basis, urging investors to take proactive steps to protect their legal rights.
See More
GeneDx Faces Securities Class Action After Stock Plunge
- Stock Price Crash: GeneDx's stock plummeted by $33.42 (-49%) on May 5, 2026, following a disastrous Q1 earnings report, severely undermining investor confidence and exposing the company to a securities class action.
- Deteriorating Financial Performance: The company reported a tenfold increase in net loss compared to the previous year, with the Fabric Genomics unit missing its revenue target by $2.5 million, leading to a $31.2 million impairment charge that significantly impacted overall financial health.
- Revenue Guidance Cut: GeneDx slashed its 2026 revenue guidance by 12%, stating that revenue growth for genome and exome would be at least 20%, a stark decline from earlier projections, indicating a major shift in product mix and negative implications for future growth.
- Legal Investigation Launched: Hagens Berman is investigating whether GeneDx intentionally or recklessly misled investors regarding the true value of Fabric Genomics and its impact on growth expectations, potentially resulting in substantial losses for investors.
See More
GeneDx Shareholder Lawsuit Reminder and Financial Loss Disclosure
- Lawsuit Application Deadline: ClaimsFiler reminds GeneDx shareholders that those who purchased or acquired shares between April 16, 2025, and May 4, 2026, must file lead plaintiff applications by August 3, 2026, to protect their rights in the securities class action lawsuit.
- Declining Financial Performance: GeneDx's financial results released on May 4, 2026, revealed a drop in adjusted gross margin from 74% to 69%, missing revenue estimates for both its exome and genome products, and lowering full-year revenue guidance to $475 million to $490 million from the previous $540 million to $550 million.
- Impairment Loss Disclosure: The company reported a $31.2 million impairment loss related to its acquisition of Fabric Genomics, which was initially expected to broaden its market opportunities, but failed to deliver the anticipated recurring revenue streams.
- Stock Price Plummet Impact: Following the disappointing financial results, GeneDx's stock price fell by $33.42, or 49.2%, significantly undermining investor confidence and potentially prompting more shareholders to join the lawsuit seeking compensation.
See More
GeneDx Securities Class Action: Lead Plaintiff Selection Deadline Approaches
- Severe Investor Losses: GeneDx Holdings Corp. shares plummeted by $33.42, a 49.20% drop, after the company disclosed a $31.2 million impairment loss, significantly undermining investor confidence and impacting the company's market performance.
- Lead Plaintiff Application Deadline: Investors must file their motions by August 3, 2026, to seek lead plaintiff status; those who miss this deadline can still participate as absent class members in any future settlement or judgment, ensuring their rights are preserved.
- Importance of Lead Plaintiff: Under the Private Securities Litigation Reform Act of 1995, the lead plaintiff directs the litigation on behalf of the entire class, making it crucial to select an investor with substantial losses to effectively represent the collective interests of shareholders.
- Litigation Process Overview: After the deadline, the court will consolidate competing lead plaintiff motions and evaluate which applicants meet PSLRA requirements, a process that typically takes several weeks, ensuring that the appointed lead plaintiff can effectively manage the case proceedings.
See More
Class Action Lawsuit Announced for GeneDx Holdings Corp.
- Class Action Initiation: Rosen Law Firm has announced a class action lawsuit on behalf of purchasers of GeneDx Holdings Corp. (NASDAQ:WGS) common stock between April 16, 2025, and May 4, 2026, indicating potential losses for investors due to misrepresentations.
- Compensation Structure: Investors joining the lawsuit can do so without any out-of-pocket expenses, as the law firm operates on a contingency fee basis, thereby reducing financial barriers and encouraging more affected parties to participate.
- Lawsuit Context: The lawsuit alleges that GeneDx made false statements regarding the impact of its acquisition of Fabric, misleading investors into believing that the acquisition would enhance financial performance, which resulted in losses when the truth emerged.
- Law Firm Reputation: Rosen Law Firm is recognized for its successful track record in securities class actions, having recovered over $438 million for investors in 2019 alone, showcasing its expertise and influence in handling similar cases.
See More
GeneDx Faces Class Action Lawsuit Risks
- Class Action Initiation: GeneDx Holdings Corp. is facing a class action lawsuit due to false statements made between April 16, 2025, and May 4, 2026, with investors able to apply as lead plaintiffs by August 3, 2026, indicating significant legal risks for the company.
- Financial Loss Disclosure: The Q1 2026 financial report revealed a drop in adjusted gross margin from 74% to 69%, and projected earnings were revised down from $540-$555 million to $475-$490 million, directly impacting the company's financial health.
- Acquisition Impact Revealed: Following the acquisition of Fabric Genomics, GeneDx reported a $31.3 million impairment loss, highlighting significant issues with the acquisition decision that could threaten future operations.
- Stock Price Plunge Reaction: Following the earnings report, GeneDx's stock price plummeted over 49%, reflecting strong market concerns regarding the company's financial condition and management transparency, which may lead to decreased investor confidence.
See More
